BridGene Biosciences
Pioneering the next era of small molecules therapeutics
United States · $80.5M raised
- Business Model
- B2B
- Website
- bridgenebio.com
- Total Funding
- $80.5M
- Last Round
- $28.0M Series BOct 2025
- Rounds
- 3
About
Chemoproteomics-driven small-molecule drug R&D for undruggable targets
Summary
BridGene Biosciences is a Biotech company based in United States. It has raised $80.5M in total across 3 rounds, most recently a $28.0M Series B round in Oct 2025. Investors include Lapam Capital, Bayland Capital and GTJA Investment Group.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2025
Sign up to see all 3 rounds
Series A through Series B — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bridgene-biosciences"><img src="https://indexed.vc/api/badge/company/bridgene-biosciences" alt="BridGene Biosciences on Indexed.vc" width="260" height="76" /></a>